EDAP

EDAP TMS SA

8 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 29

Classification of legacy segments as discontinued operations to focus on high-margin therapeutics.

divestiture

70%

neutralMay 29

Corporate rebranding to FocalTherics and ticker change to FOCL.

management change

50%

bearishMay 7

Net loss widened to $9.1 million despite strong revenue growth.

earnings miss

70%

bullishMay 7

Gross margin increased to 45.7% due to higher HIFU mix.

margin expansion

60%

neutralMay 7

Drawdown of Tranche B credit facility to support operations.

capital raise

50%

bearishMay 7

Issuance of warrants as a condition for EIB financing.

dilution risk

40%

bearishMay 7

Net loss widened to $9.1 million despite strong revenue growth.

earnings miss

70%

bullishMay 7

Gross margin increased to 45.7% due to higher HIFU mix.

margin expansion

60%

neutralMay 7

Drawdown of Tranche B credit facility to support operations.

capital raise

50%

bearishMay 7

Issuance of warrants as a condition for EIB financing.

dilution risk

40%

bearishMay 7

Net loss widened to $9.1 million despite strong revenue growth.

earnings miss

70%

bullishMay 7

Gross margin increased to 45.7% due to higher HIFU mix.

margin expansion

60%

neutralMay 7

Drawdown of Tranche B credit facility to support operations.

capital raise

50%

bearishMay 7

Issuance of warrants as a condition for EIB financing.

dilution risk

40%

bearishMay 7

Net loss widened to $9.1 million despite strong revenue growth.

earnings miss

70%

bullishMay 7

Gross margin increased to 45.7% due to higher HIFU mix.

margin expansion

60%

neutralMay 7

Drawdown of Tranche B credit facility to support operations.

capital raise

50%

bearishMay 7

Issuance of warrants as a condition for EIB financing.

dilution risk

40%

bearishMay 7

Net loss widened to $9.1 million despite strong revenue growth.

earnings miss

70%

bullishMay 7

Gross margin increased to 45.7% due to higher HIFU mix.

margin expansion

60%

neutralMay 7

Drawdown of Tranche B credit facility to support operations.

capital raise

50%

bearishMay 7

Issuance of warrants as a condition for EIB financing.

dilution risk

40%

bearishMay 7

Net loss widened to $9.1 million despite strong revenue growth.

earnings miss

70%

bullishMay 7

Gross margin increased to 45.7% due to higher HIFU mix.

margin expansion

60%

neutralMay 7

Drawdown of Tranche B credit facility to support operations.

capital raise

50%

bearishMay 7

Issuance of warrants as a condition for EIB financing.

dilution risk

40%

bearishMay 7

Net loss widened to $9.1 million despite strong revenue growth.

earnings miss

70%

bullishMay 7

Gross margin increased to 45.7% due to higher HIFU mix.

margin expansion

60%

neutralMay 7

Drawdown of Tranche B credit facility to support operations.

capital raise

50%

bearishMay 7

Issuance of warrants as a condition for EIB financing.

dilution risk

40%

Filing History

8-KMay 29, 2026

EDAP TMS SA is attempting a high-stakes identity shift, moving from a diversified medical device provider to a focused therapeutic entity under the name FocalTherics. The decision to treat legacy segments as discontinued operations creates a stark divide in investor interpretation: it is either a sophisticated streamlining of the business to unlock value or a strategic accounting move to hide deteriorating core performance. The upcoming Investor Day on June 1 will be the critical juncture where management must prove that the new focal therapy strategy can generate sufficient growth to offset the loss of legacy cash flows.

10-QMay 7, 2026

The latest filing reveals a company in the midst of a high-stakes transition. EDAP is successfully shedding its legacy ESWL and Distribution businesses—both of which saw revenue declines of 16% and 21% respectively—to bet the entire enterprise on the HIFU platform. The growth in Focal One sales and the expansion of the US footprint are genuine positive signals, but they are currently offset by a burn rate that continues to erode shareholders' equity. Investors are now faced with a classic trade-off between explosive early-stage growth and severe liquidity risk. While the strategic pivot to a recurring-revenue model is working on a unit level, the corporate level is struggling with debt service and administrative overhead. The success of the company now depends on whether the HIFU adoption curve can accelerate fast enough to reach profitability before the current cash runway and EIB credit facility are exhausted.